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Summary 
Although there is a mounting body of evidence that eosinophils are recruited to sites of allergic 
inflammation by a number of ~-chemokines, particularly eotaxin and RANTES, the receptor 
that mediates these actions has not been identified. We have now cloned a G protein-coupled 
receptor, CC CKR3, from human eosinophils which, when stably expressed in AML14.3D10 
cells bound eotaxin, MCP-3 and R_ANTES with Kas of 0.1, 2.7, and 3.1 nM, respectively. CC 
CKR3 also bound MCP-1 with lower affinity, but did not bind MIP-10~ or MIP-I[~. Eotaxin, 
RANTES, and to a lessor extent MCP-3, but not the other chemokines, activated CC CKR3 
as determined by their ability to stimulate a CaZ+-flux.  Competition binding studies on primary 
eosinophils gave binding at~inities for the different chemokines which were indistinguishable 
from those measured with CC CKR3.  Since CC CKR3 is prominently expressed in eosino- 
phils we conclude that CC CKR3 is the eosinophil eotaxin receptor. Eosinophils also express a 
much lower level of a second chemokine receptor, CC CKR1, which appears to be responsi- 
ble for the effects of MIP-llx. 
E 
osinophils play prominent roles in a variety of atopic 
conditions including allergic rhinitis,  dermatitis,  con- 
junctivitis, and bronchial asthma (1, 2). A pivotal event in 
the  process is  the  accumulation of eosinophils  at  the  in- 
volved sites. While a number of the classical chemoattractants, 
including CSa, LTB4, and PAF, are known to attract eosi- 
nophils  (1),  these mediators are promiscuous,  acting on a 
variety ofleukocytes including neutrophils, and are unlikely 
to be responsible for the selective accumulation of eosino- 
phils. In contrast, the [3-chemokines, a family of 8-10-kD 
secreted proteins, are more restricted in the leukocyte sub- 
types they target (3), and studies from a variety of  laboratories 
have implicated several as candidates for the recruitment of 
eosinophils  in  atopic  diseases.  In  particular,  RANTES, 
MCP-3,  MIP-lo~,  and most recently, eotaxin, have been 
shown to activate eosinophils in vitro (4-6), and RANTES 
and eotaxin to selectively attract eosinophils in vivo (7, 8). 
Moreover, eotaxin is generated during antigen challenge in 
the guinea pig model of  allergic airway inflammation (9, 10). 
While  elucidation  of the  actions  of [3-chemokines  on 
eosinophils has contributed greatly to our understanding of 
eosinophil biology, information regarding the  cell surface 
receptors  that  mediate  these  effects remains  sparse.  The 
known ~-chemokine receptors are members of the G pro- 
tein-coupled receptor superfamily. Although two of these 
receptors, CC  CKR1  (11-13,  Daugherty, B.,  manuscript 
in preparation)  and CC  CKR2  (MCP-1R)  (14-16)  have 
been  extensively characterized,  neither  has  the  necessary 
ligand selectivity or the appropriate expression patterns to 
mediate  the  effects of the  [3-chemokines on  eosinophils. 
Therefore, we initiated an effort to identify and character- 
ize eosinophil-specific chemokine receptors. In this report 
we describe the properties of a third [~-chemokine receptor, 
CC  CKR3,  cloned from primary eosinophils,  and  func- 
tionally expressed in AML14.3D10 cells. This receptor has 
the expected ligand specificity as it binds the potent eosino- 
phil attractants, eotaxin, RANTES, and MCP-3 with high 
affinity. Correlation with the binding properties of primary 
eosinophils provides compelling evidence that CC  CKR3 
is the primary endogenous receptor that mediates the  ef- 
fects of B-chemokines on eosinophils. Eosinophils also ex- 
press a much lower level of CC CKR1, a receptor that ap- 
pears to be responsible for the effects of MIP-lo~. 
Materials and Methods 
cDNA Cloning of CC CKR3.  Total  human  eosinophil RNA 
was purified and used in an RT/PCR reaction (17) with the fol- 
lowing  oligonucleotide primers designed from  the  human  CC 
CKR1  and  CC  CKR2  cDNAs  (11, 14): 5'-AACCTGGC- 
CAT(C,T)TCTGA-(C,T)CTGC-3'; 5'-GAAC(C,T)TCTC(C,A)- 
CCAACGAAGGC-3. The remaining 5' and 3' sequence encod- 
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(RACE)  with  the  following primers:  5'-TCTCGCTGTACA- 
AGCCTGTGTG-Y  (5'-RACE);  5'-CCTI'CTCTCTTCCTA- 
TCAATCC-Y (Y-RACE). The RACE products  were  sequenced 
and the initiation and termination codons (TAG) identified. For 
expression  of  CC  CKR3,  a  new  set  of  PCR  primers  were 
designed to reamplify the entire coding region: 5'-ATATATTAA- 
GCTTCCACCATGACAACCTCACTAGATACAG-Y;  5'-ATA- 
TATTCTAGAGCGGCCGCTAAAACACAATAGAGAGTTCC- 
3'. The resultant PCR product was subcloned into the expression 
vector pBJ/NEO  (Daugherty,  B.,  manuscript in preparation)  to 
yield pBJ/NEO/CCCKR3.  Several clones were  sequenced and 
one clone comprising the consensus sequence was chosen for ex- 
pression of CC CKR3 in heterologous cells. 
Transfection into AML14.3D10 Cells.  Transfection into AML 
14.3D10 cells  (18) was performed as described (19).  Stable clones 
were generated by selection in medium containing 2 mg/ml Ge- 
neticin for  8-10  d  until individual surviving clusters  appeared. 
Clones were derived from these clusters by limiting dilution and 
assayed by Western blotting and ligand-induced Ca  ~+ flux. 
Purification of Eosinophils.  Prhnary eosinophils were isolated from 
granulophoresis preparations (20) obtained from allergic and asth- 
matic  donors.  The  granulocytes were  purified  (21)  and  subse- 
quently treated with  anti-CD16 microbeads  (Mihenyi Biotech, 
Auburn,  CA)  followed by MACS  separation  (22).  Eosinophils 
were typically >99% pure. 
Generation of e~-CC CKR3 Antisera and Immunoblotting.  Poly- 
clonal  rabbit  antisera  was  generated  to  CC  CKR3  using the 
COOH-terminal decapeptide sequence TAEPELSIVF (23).  SDS 
PAGE  (24)  was  carried  out  with  whole  cells  on  4-20%  gels 
(Novex, San Diego, CA), and immunoblotting was performed as 
described (Novex). 
Assays.  Recombinant chemokines were obtained from Pep- 
roTech (Rocky Hill, NJ).  ~2SI-MCP-3 and ~2SI-MIP-lo~ was ob- 
tained from DuPont NEN (Boston, MA) and ~25I-human-eotaxin 
from Amersham (Arlington Heights, IL).  Binding of ~25I-labeled 
ligands (typically a total of 2 ￿  104 cpm) in the presence of varying 
concentrations of unlabeled ligands to intact cells (typically 1.5  ￿ 
104 , 10  s, or 106 for experiments with labeled eotaxin, MCP-3, or 
MIP-la, respectively) were performed at 32~  as described (25). 
Ligand-induced Ca  ~+  fluxes  in  transfected  AML14.3D10  cells 
were performed with indo-1 as described (25). 
Results  and  Discussion 
Orphan  Cloning  of an  Eosinophil  ~-Chemokine  Receptor. 
The previously characterized  ~3-chemokine receptors,  CC 
CKR1  (11)  and CC  CKR2  (14),  share substantial homol- 
ogy  in transmembrane helices  II  and VII.  Using an P,T/ 
PCR  strategy based on this homology,  we  cloned a  novel 
open reading frame from total human eosinophil RNA  which 
codes  for  a  protein  of 355  amino acids.  The  sequence  of 
this protein, designated CC CKt<3, is 63% and 51% identi- 
cal to CC CKR1,  and CC  CKR2B,  its two closest homo- 
logues  (Fig.  1).  This  sequence  is  also  identical to  that  re- 
ported by Combadiere  et al.  (26)  except that  it contains a 
lysine in place of asparagine at position 107. We have con- 
firmed  our  sequence  by analysis  of genomic  clones.  The 
discrepancy is unlikely to be due to genetic polymorphisrn 
since  all or-  and  [~-chemokine  receptors  analyzed  to  date 
contain lysine in  that  position  including the  recently  de- 
scribed basophilic [3-chemokine receptor  (27),  CC  CKR1 
(11),  MCP-1R  (14),  IL-8RA  and  IL-8RB  (28,  29),  the 
three  murine  [3-chemokine  receptors  (30,  31)  as  well  as 
three  human  chemokine-like  receptors  (32-34).  An  un- 
usual feature ofCC  CKR3, in contrast to other chemokine 
receptors,  is the  cluster of negatively charged  amino acids 
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Figure  1.  Amino  acid  se- 
quence  alignment  of  human 
[3-chemokine receptors. The fig- 
ure  shows the  predicted  se- 
quences  for  CC  CKR3,  CC 
CKR1  (11), CC  CKtl.2B  (14), 
CC CKP,4 (27), and V28  (33). 
The positions of the seven puta- 
tive transmembrane-spanning re- 
gions are designated with  over- 
lines.  A  minimum  of  three 
identical residues is indicated in 
the shaded region. The complete 
nucleotide  sequence  of  CC 
CKR3 is available from EMBL/ 
GenBank/DDBJ  under accession 
number U51241. Figure  2.  Expression of  CC 
CKR.3. Western blots on eosino- 
phils  (lane  I);  CC  CK/L3  ex- 
pressing  clone,  3.16  (lane  2); 
nonexpressing  clone,  3.49  (lane 
3); PMN  (lane 4); and untrans- 
fected  AML14.3D10  (lane 5). 
106 cells were used in each lanes 
1 and 4 and 2.5 X 105 cells were 
used  in lanes 2,  3,  and 5.  Pre- 
immune  sera gave no  positive 
bands (data not shown). 
(ETEELFEET) distal to transmembrane helix IV in the sec- 
ond extracellular loop. 
Expression  of the  Human  CC  CKR3  in  AML14.3D10 
Cells.  AML14.3D10 was transfected with CC  CKR.3 and 
stable clones selected for neomycin resistance.  To  demon- 
strate expression of receptor protein, a Western blot was per- 
formed  using antisera  generated  against  a  peptide  derived 
from  the  predicted  COOH-terminus  of CC  CKP,3.  As 
shown in Fig. 2, prominent immunoreactive bands migrat- 
ing at 45-55 kD are present in primary eosinophils (lane  1) 
and clone 3.16  (lane 2),  indicating that  these  cells express 
CC  CKtL3.  The bands recognized by the antisera are spe- 
cific  since  they  are  not  present  in  either  untransfected 
AML14.3D10 cells (lane 5), or in neutrophils (lane 4). Fur- 
thermore,  the  immunoreactive  bands  are  absent  in  clone 
3.49  (lane 3),  indicating that this neomycin-resistant clone 
is a non-expressor ofCC  CKR3.  Clone 3.49 therefore was 
used as a  negative control in subsequent experiments.  The 
sharp  45-kD  immunoreactive  band  present  in  the  3.16 
clone, but not in eosinophils, is likely to represent the non- 
glycosylated form of the receptor. 
Binding  to  CC  CKR3  on  Intact AML14/CCCKR3.16 
Cells.  Competition binding studies were  performed with 
125I-eotaxin on clone 3.16 in order to characterize the phar- 
macological properties of CC  CKtL3. As shown in Fig. 3  a 
and  Table  1,  unlabeled human  and  murine  eotaxin  both 
competed  with Kas of 0.1  nM.  Scatchard  analysis demon- 
strated that the eotaxins bound with a single affinity and that 
clone 3.16 expressed 4  X  105 receptors/cell (data not shown). 
This activity is due to CC  CKR.3 since neither nonimmu- 
noreactive clones, such as 3.49,  nor untransfected cells dis- 
played any specific binding (data not shown).  Clearly,  CC 
CKIL3 is a high affinity receptor for eotaxin. Cross-compe- 
tition studies  with  other  [3-chemokines known  to  be  po- 
tent  eosinophil  chemoattractants,  MCP-3  and  RANTES, 
demonstrated  that  they bound to  CC  CKtL3  with Kas  of 
about 3  nM  (Fig.  3  a,  Table  1).  In contrast, MCP-1  com- 
peted with much lower affinity (Ka  =  60  nM),  and MIP- 
lot,  MIP-1[3  (Fig.  3  a,  Table  1),  and  the  cx-chemokine, 
IL-8 (data not shown), failed to compete at all. 
Table  1.  Binding  Affinities of Various Chemokines Comparing 
CC CKR3 Expressed in AML14.3010 with Primary Eosinophils 
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Equilibrium binding of [~-chemokines to AML14.3D10 cells 
expressing CC CKR3 and to primary eosinophils. Increasing concentra- 
tions of unlabeled human eotaxin  (I), murine eotaxin  (O),  ILANTES 
([3), MCP-3  (O),  or MCP-1  (#)  were  used to  compete  against fixed 
concentrations  of either  12SI-human  eota.xin (a and c), or 125I-MCP-3 (b 
and d).  Also shown are  competition with  100  nM concentrations of 
MIP-lcx (O), and MIP-I[3 (A). The experiments were carried out either 
with CC CKR3 expressing clone, 3.16 (a and b), or with native eosino- 
phils (c and d). All values are the averages of triplicate determinations. 
Typically, 4,000-6,000  cpm ofiodinated ligand was bound in the absence 
of competitor  with S/N ratios exceeding  15. Results  are representative 
single experiments  except data for MIP-lcx  and MIP-I[3 which are the 
averages of 3-7 experiments. 
Competitor  CC CKR3  Eosinophils 
Kd (nM) 
uSl-human eotaxin 
Human-eotaxin  0.1  _+ 0.04  (4)  0.1  +  0.03  (3) 
Murine-eotaxin  0.1  ___ 0.04  (3)  0.1  +  0.01  (2) 
MCP-3  2.7 +  1.7  (5)  3.0 +  0.2  (2) 
RANTES  3.1  •  0.6  (5)  2.6 •  0.3  (2) 
MCP-1  60 +  9  (3)  41  •  2  (2) 
MIP-lot  N.B.  (4)  N.B.  (2) 
MIP-113  N.B.  (4)  N.B.  (2) 
125I_MCP_3 
Human-eotaxin  0.2 ___ 0.1  (4)  0.2 •  0.1  (2) 
Murine-eotaxin  0.3 •  0.1  (2)  0.2 +  0.1  (3) 
MCP-3  0.7 +_ 0.4  (4)  1.1  +  0.6  (i0) 
R.ANTES  0.5 •  0.3  (4)  0.9 +  0.4  (8) 
MCP-1  16 +  2  (3)  61  •  13  (2) 
MIP-lct  N.B.  (4)  See text 
MIP-I[3  N.B.  (4)  N.B.  (2) 
Competition binding experiments  were  carried  out against the indi- 
cated iodinated ligand as described in the legend of Fig. 2 and in Mate- 
rials and Methods.  All results are the averages of the number of experi- 
ments shown in parenthesis.  KdS were calculated using LIGAND (36). 
N.B., no competition was observed. 
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12SI-MCP-3. Again, human and murine  eotaxin competed 
strongly with Kas of 0.2 and 0.3 nM, respectively (Fig 3  b, 
Table  1).  MCP-3  and  RANTES  also  demonstrated  high 
affinity, with KdS of 0.7 and 0.5 nM, values about fourfold 
lower  than  measured  against  12SI-eotaxin.  MCP-1  com- 
peted  weakly  (Ka  =  16  nM),  and  MIP-l~x,  and  MIP-113 
failed to compete at all. Thus, despite small quantitative dif- 
ferences, the overall ligand selectivity of the receptor is the 
same whether measured by competition against eotaxin or 
MCP-3,  and  the  order  of potency,  eotaxin>MCP-3  = 
RANTES>>MCP-1,  is identical. 
CC CKR3  Is Functionally Coupled in AML14.3D10  Cells. 
To  determine  whether  CC  CKR3  was  functionally  cou- 
pled  in  AML14.3010  cells,  intracellular  Ca  2+  levels  were 
measured in response to various 13-chemokines. As shown 
in  Fig.  4,  eotaxin  and  RANTES  induced  Ca2+-fluxes  in 
cells  expressing the receptor with EDs0s of 0.3 and 10 nM, 
values consistent with their binding affinities.  Surprisingly, 
100 nM of MCP-3 was required to induce a response, and 
that  response  was smaller than  those observed for eotaxin 
or RANTES  (Fig.  4).  No response  was  generated  by the 
addition  ofMIP-lo~, MIP-1[3, MCP-1  or IL-8 at concen- 
trations as high as  1 txM  (data not shown)L The responses 
to eotaxin,  RANTES,  and MCP-3 are due to the specific 
expression of CC CKR3 since none of these mediators in- 
duced fluxes in untransfected  cells  (data not shown),  or in 
clone 3.49 (negative control; Fig. 4). 
Binding Properties of Pn'mary Eosinophils.  The  selectivity  of 
CC CKR3 for the various 13-chemokines mirrors the effec- 
tiveness of these ligands as eosinophil chemoattractants sug- 
gesting that CC CKR.3 is the primary mediator ofchemokine 
I  Combadiere et al. (26) have reported cloning a receptor that differs by 
only one amino acid from the sequence reported in the present commu- 
nication. While their very preliminary functional characterization differs 
greatly from ours, they were unable to demonstrate any specific binding 
to cells putatively expressing the receptor, and their functional data have 
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Figure  4.  Human  eotaxin, 
RANTES and MCP-3 are ago- 
nists for CC CKR3. Ca2+-fluxes 
were  induced  in  CC  CKR3- 
expressing clone 3.16 by  addi- 
tion  of eotaxin, RANTES,  or 
MCP-3 at 0.03 nM (17); 0.3 nM 
(A); 3 nM (f-q); 10 nM (11); 30 
nM (A); and  100 nM (O). Re- 
sponses  of  the  non-expressing 
clone 3.49 to  100  nM  of each 
chemokine (O) are used as con- 
trols. 
induced eosinophil chemotaxis. To provide additional phar- 
macological evidence we conducted binding studies on pri- 
mary eosinophils.  When measured by competition against 
12SI-eotaxin, unlabeled human eotaxin gave a Kd of 0.1 nM, 
a  value  identical  to  that  obtained  on  cloned  CC  CK1K3 
(Fig. 3 c, Table  1). Scatchard analysis showed a single bind- 
ing affinity, and 4  X  10  5 sites/cell  averaged over three do- 
nors  (data  not  shown).  The  affinities  for  RANTES  and 
MCP-3 were indistinguishable from those measured on CC 
CKR3, and as with CC CKIL3, MIP-lo~ and MIP-II3 did 
not  exhibit  any  ability  to  compete  with  radiolabeled  eo- 
taxin (Fig. 3, a and c, Table  1).  Similarly,  the Kas obtained 
by  competition  against  lesI-MCP-3  on  eosinophils  were 
within twofold of those measured against cloned CC CKIK3 
(Fig. 3, b and d, Table  1). All of the observations and mea- 
surements,  taken  together with the Western  blots  (Fig.  2) 
showing expression ofCC  CK1K3, verify that CC CK1K3 is 
the  eosinophil  eotaxin  receptor,  and  appears  to be largely 
responsible for mediating the effects of most [3-chemokines 
on eosinophils. 
Eosinophils Also Express CC CKR1 at Low Levels.  One  dif- 
ference  between  data  obtained  with  eosinophils  and  that 
with cloned CC  CKR3 is that MIP-lci partially inhibited 
the  binding  of 125I-MCP-3  on  eosinophils  (Fig.  3  d).  To 
invesfgate the nature of the site responsible for these effects, 
detailed  studies  were  carried  out  by  competition  against 
125I-MIP-lci.  As shown  in  Fig.  5,  MIP-1oq MCP-3,  and 
RANTES all competed strongly with ICs0s of 0.3, 0.7, and 
0.9  riM,  respectively.  In contrast,  human  and routine  eo- 
taxin competed with relatively low affinity, showing ICs0s 
of 45 and ll  nM, respectively, while the affinity of MCP-1 
is  even lower with  an  IC50 of 120 nM.  These pharmaco- 
logical characteristics  are clearly distinct from those of CC 
CKR3, but are identical to those we have reported for CC 
CKR1  expressed in RBL2H3 cells  (Daugherty, B., manu- 
script in preparation).  Scatchard analysis shows 0.5-2  ￿  104 
sites/cell,  only  1-5%  the  level  of CC  CKR3  (data  not 
shown). 
120 
.r  ~  * 
._o  80  ",  ',  ". 
K  4o  ~.  0'~-  ,, 
~"  20  ~'.0",  \ 
0  o -~;z::-~ 
I  I  I  I 
-13  -11  -9  -7 
Log [Unlabeled Ligand]  (M) 
Figure  5.  Pharmacology of the MIP-lo~ binding site on eosinophils. 
Increasing concentrafons of unlabeled human eotaxin (11), murine eo- 
taxin (O), RANTES  ([[]), MCP-3  (0),  MCP-1  (@), or MIP-la  (O) 
were used to compete against a fixed concentration of ~251-MIP-lcx  as de- 
scribed in Fig. 3. 
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count for the reported effects of ~-chemokines on eosino- 
phils.  As  discussed  above,  the  data  strongly  support  the 
conclusion that CC  CKR3 is the eotaxin receptor.  While 
the  properties  of the  two  receptors  indicate  that  either  is 
capable of mediating the activity of RANTES and MCP-3, 
CC CKR3 is probably the primary transducer since it is ex- 
pressed at 20-80 times the level of CC CKR.1  (4  ￿  10  s vs. 
0.5-2  ￿  104 sites/cell),  a  difference that more  than  com- 
pensates  for the  greater affimty of CC CKI~I for the  two 
chemokines. MIP-lct must act through CC CKR.1 as it binds 
strongly to and activates  this  receptor  (11,  Daugherty,  B., 
manuscript in preparation), but does not bind to CC CKR3. 
The identification  of the  two [3-chemokine eosinophil re- 
ceptors is consistent with predictions made from heterolo- 
gous  desensitization  experiments.  Based  on  these  studies 
Dahinden  et al.  (4)  postulated the existence  of two recep- 
tors,  one that is actwated by R.ANTES and MCP-3, and a 
second  that  is  activated  by  MIP-I~,  R.ANTES,  and  by 
MCP-3.  Although  those  studies  predate  the  discovery of 
eotaxin,  the  properties  of the  first  receptor  are  consistent 
with CC CK_R3, and those of the second with CC CKIL1. 
CC CKR3 is the third [3-chemokine receptor to be ex- 
tensively characterized, and like CC CKR1 and CC CKR2 
it binds and is acuvated by multiple ligands. The selectivities 
of the  three  receptors  overlap,  but  are  not  identical:  CC 
CKR1  binds  MCP-3,  R.ANTES,  and  MIP-lot  (11-13, 
Daugherty,  B.,  manuscript  m  preparation),  CC  CKR2 
binds MCP-1  and MCP-3  (14,  16),  and CC CKR3 is se- 
lective for eotaxin,  R_ANTES and MCP-3. While there as 
little  correlation between overall sequence homology of the 
[3-chemokines  and  the  receptors  they  target,  local  motifs 
must  exist  which  control  specificity.  Elucidation  of those 
motifs  should  significantly  advance  structurally  based  ap- 
proaches  to  develop  selective  antagonists  for  the  different 
receptors. 
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